BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

...companies’ lead cell-based cancer vaccines are in Phase II testing. DCPrime investors, including majority shareholder Van Herk Investments...
BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

With a steady stream of small investments from the Van Herk Group, DCprime is now poised to raise its next financing from a broader group of investors to expand the Dutch cancer vaccine company’s product...
BioCentury | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

...DKK559.6 million ($82.4 million) via a private placement and directed share issue to existing investor Van Herk Investments...
Items per page:
1 - 3 of 3
BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

...companies’ lead cell-based cancer vaccines are in Phase II testing. DCPrime investors, including majority shareholder Van Herk Investments...
BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

With a steady stream of small investments from the Van Herk Group, DCprime is now poised to raise its next financing from a broader group of investors to expand the Dutch cancer vaccine company’s product...
BioCentury | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

...DKK559.6 million ($82.4 million) via a private placement and directed share issue to existing investor Van Herk Investments...
Items per page:
1 - 3 of 3